Jacksoneye SC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$103,564	5
2021	Research	$44,381	8
2020	Research	$25,054	5
2019	Research	$194,831	5

Breakdown

Who paid Research payments · program years 2019–2022

Allergan Inc. $214,184 9 payments
AbbVie, Inc. $87,826 5 payments
Bausch Health US, LLC $32,173 6 payments
Novartis Pharmaceuticals Corporation $27,945 2 payments
EyePoint Pharmaceuticals US, Inc. $5,700 1 payment

Studies the money was for Research payments · program years 2019–2022

Multicenter Double Masked Randomized Vehicle-Controlled Parallel-Group study of AGN-190584 for Participants with Presbyopia $214,184 9 payments
A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) $79,503 2 payments
A Prospective, Multicenter, Randomized, Active-Controlled Clinical Study to Evaluate the Safety and Effectiveness of the Envista One-Piece Hydrophobic Acrylic Trifocal Intraocular Lens in Subjects Undergoing Cataract Extraction $32,173 6 payments
A Randomized, Placebo-Controlled, Double-Masked, Multi-Center, Dose-Ranging Study to Evaluate the Safety, and Efficacy of Unr844 in Subjects With Presbyopia $27,945 2 payments
Currently available treatments for presbyopia (old eye) include nonsurgical options (spectacles or contact lenses) and surgical options, however, each has its own risks and limitations. The purpose of this study is to evaluate how effective AGN-190584 is in treating presbyopia compared to vehicle (placebo). $6,201 2 payments
DEXYCU Retrospective study $5,700 1 payment
A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of BID Dosing of AGN-190584 in Subjects with Presbyopia $2,122 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.